NIAID  July 20, 2022 NIAID and its partners under the Chemical Countermeasures Research Program (CCRP) invite applications for the early-stage development of therapeutics and medical countermeasures (MCMs) to mitigate the adverse health effects resulting from toxic chemical exposure, including validation of therapeutic targets and preclinical characterization of lead compounds. Through the funding opportunity announcement (FOA) CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3, Clinical Trial Not Allowed), the ultimate aim is to generate well-characterized therapeutic candidates that may one day advance the nation’s medical and public health preparedness for, response to, and recovery from chemical-related […]